|
1
|
Momenimovahed Z, Tiznobaik A, Taheri S and
Salehiniya H: Ovarian cancer in the world: Epidemiology and risk
factors. Int J Womens Health. 11:287–299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Viale PH: The American cancer society's
facts & figures: 2020 Edition. J Adv Pract Oncol. 11:135–136.
2020.PubMed/NCBI
|
|
3
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delgado-Ortega L, González-Domínguez A,
Borrás JM, Oliva-Moreno J, González-Haba E, Menjón S, Pérez P,
Vicente D, Cordero L, Jiménez M, et al: The economic burden of
disease of epithelial ovarian cancer in Spain: The OvarCost study.
Eur J Health Econ. 20:135–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Orr B and Edwards RP: Diagnosis and
treatment of ovarian cancer. Hematol Oncol Clin North Am.
32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuroki L and Guntupalli SR: Treatment of
epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Purdie DM, Bain CJ, Webb PM, Whiteman DC,
Pirozzo S and Green AC: Body size and ovarian cancer: Case-control
study and systematic review (Australia). Cancer Causes Control.
12:855–863. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li YC, Park MJ, Ye SK, Kim CW and Kim YN:
Elevated levels of cholesterol-rich lipid rafts in cancer cells are
correlated with apoptosis sensitivity induced by
cholesterol-depleting agents. Am J Pathol. 168:1107–1118.
1404–1405. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dulak J and Józkowicz A: Anti-angiogenic
and anti-inflammatory effects of statins: Relevance to anti-cancer
therapy. Curr Cancer Drug Targets. 5:579–594. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jakobisiak M and Golab J: Potential
antitumor effects of statins (Review). Int J Oncol. 23:1055–1069.
2003.PubMed/NCBI
|
|
11
|
Irvin S, Clarke MA, Trabert B and
Wentzensen N: Systematic review and meta-analysis of studies
assessing the relationship between statin use and risk of ovarian
cancer. Cancer Causes Control. 31:869–879. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lavie O, Pinchev M, Rennert HS, Segev Y
and Rennert G: The effect of statins on risk and survival of
gynecological malignancies. Gynecol Oncol. 130:615–619. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olsen CM, Green AC, Whiteman DC, Sadeghi
S, Kolahdooz F and Webb PM: Obesity and the risk of epithelial
ovarian cancer: A systematic review and meta-analysis. Eur J
Cancer. 43:690–709. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mohammadian-Hafshejani A, Sherwin CMT and
Heidari-Soureshjani S: Do statins play any role in reducing the
incidence and mortality of ovarian cancer? A systematic review and
meta-analysis. J Prev Med Hyg. 61:E331–E339. 2020.PubMed/NCBI
|
|
15
|
Majidi A, Na R, Dixon-Suen S, Jordan SJ
and Webb PM: Common medications and survival in women with ovarian
cancer: A systematic review and meta-analysis. Gynecol Oncol.
157:678–685. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X and Zhou J: Impact of postdiagnostic
statin use on ovarian cancer mortality: A systematic review and
meta-analysis of observational studies. Br J Clin Pharmacol.
84:1109–1120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. 2010.Available online at:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspSeptember
10–2022
|
|
18
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Irwig L, Macaskill P, Berry G and Glasziou
P: Bias in meta-analysis detected by a simple, graphical test.
Graphical test is itself biased. BMJ. 316:470–471. 1998.PubMed/NCBI
|
|
20
|
Elmore RG, Ioffe Y, Scoles DR, Karlan BY
and Li AJ: Impact of statin therapy on survival in epithelial
ovarian cancer. Gynecol Oncol. 111:102–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Urpilainen E, Marttila M, Hautakoski A,
Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J,
Puistola U, Hinkula M and Läärä E: Prognosis of ovarian cancer in
women with type 2 diabetes using metformin and other forms of
antidiabetic medication or statins: A retrospective cohort study.
BMC Cancer. 18:7672018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Habis M, Wroblewski K, Bradaric M, Ismail
N, Yamada SD, Litchfield L, Lengyel E and Romero IL: Statin therapy
is associated with improved survival in patients with
non-serous-papillary epithelial ovarian cancer: A retrospective
cohort analysis. PLoS One. 9:e1045212014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vogel TJ, Goodman MT, Li AJ and Jeon CY:
Statin treatment is associated with survival in a nationally
representative population of elderly women with epithelial ovarian
cancer. Gynecol Oncol. 146:340–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Verdoodt F, Kjaer Hansen M, Kjaer SK,
Pottegård A, Friis S and Dehlendorff C: Statin use and mortality
among ovarian cancer patients: A population-based cohort study. Int
J Cancer. 141:279–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Majidi A, Na R, Jordan SJ, De Fazio A and
Webb PM; OPAL Study Group, : Statin use and survival following a
diagnosis of ovarian cancer: A prospective observational study. Int
J Cancer. 148:1608–1615. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Couttenier A, Lacroix O, Vaes E, Cardwell
CR, De Schutter H and Robert A: Statin use is associated with
improved survival in ovarian cancer: A retrospective
population-based study. PLoS One. 12:e01892332017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bar D, Lavie O, Stein N, Feferkorn I and
Shai A: The effect of metabolic comorbidities and commonly used
drugs on the prognosis of patients with ovarian cancer. Eur J
Obstet Gynecol Reprod Biol. 207:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harding BN, Delaney JA, Urban RR and Weiss
NS: Use of statin medications following diagnosis in relation to
survival among women with ovarian cancer. Cancer Epidemiol
Biomarkers Prev. 28:1127–1133. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Feng JL, Dixon-Suen SC, Jordan SJ and Webb
PM: Statin use and survival among women with ovarian cancer: An
Australian national data-linkage study. Br J Cancer. 125:766–771.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanley GE, Kaur P, Berchuck A, Chase A,
Grout B, Deurloo CM, Pike M, Richardson J, Terry KL, Webb PM and
Pearce CL: Cardiovascular medications and survival in people with
ovarian cancer: A population-based cohort study from British
Columbia, Canada. Gynecol Oncol. 162:461–468. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim DS, Ahn HS and Kim HJ: Statin use and
incidence and mortality of breast and gynecology cancer: A cohort
study using the national health insurance claims database. Int J
Cancer. 150:1156–1165. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen HY, Wang Q, Xu QH, Yan L, Gao XF, Lu
YH and Wang L: Statin as a combined therapy for advanced-stage
ovarian cancer: A propensity score matched analysis. Biomed Res
Int. 2016:91252382016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nielsen SF, Nordestgaard BG and Bojesen
SE: Statin use and reduced cancer-related mortality. N Engl J Med.
367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang A, Aragaki AK, Tang JY, Kurian AW,
Manson JE, Chlebowski RT, Simon M, Desai P, Wassertheil-Smoller S,
Liu S, et al: Statin use and all-cancer survival: Prospective
results from the women's health initiative. Br J Cancer.
115:129–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Surveillance Epidemiology and End Results
Program, Ovary Cancer Survival Statistics, . http://seer.cancer.gov/statfacts/html/ovary.html2021April
21–2021
|
|
36
|
Kwan ML, Habel LA, Flick ED, Quesenberry
CP and Caan B: Post-diagnosis statin use and breast cancer
recurrence in a prospective cohort study of early stage breast
cancer survivors. Breast Cancer Res Treat. 109:573–579. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahern TP, Pedersen L, Tarp M,
Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT and Lash TL:
Statin prescriptions and breast cancer recurrence risk: A Danish
nationwide prospective cohort study. J Natl Cancer Inst.
103:1461–1468. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cruz PMR, Mo H, McConathy WJ, Sabnis N and
Lacko AG: The role of cholesterol metabolism and cholesterol
transport in carcinogenesis: A review of scientific findings,
relevant to future cancer therapeutics. Front Pharmacol. 4:1192013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao J, Zhi Z, Wang C, Xing H, Song G, Yu
X, Zhu Y, Wang X, Zhang X and Di Y: Exogenous lipids promote the
growth of breast cancer cells via CD36. Oncol Rep. 38:2105–2115.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Camarda R, Zhou AY, Kohnz RA, Balakrishnan
S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, et
al: Inhibition of fatty acid oxidation as a therapy for
MYC-overexpressing triple-negative breast cancer. Nat Med.
22:427–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu H, Liang SL, Kumar S, Weyman CM, Liu W
and Zhou A: Statins induce apoptosis in ovarian cancer cells
through activation of JNK and enhancement of Bim expression. Cancer
Chemother Pharmacol. 63:997–1005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Niemi RJ, Braicu EI, Kulbe H, Koistinen
KM, Sehouli J, Puistola U, Mäenpää JU and Hilvo M: Ovarian tumours
of different histologic type and clinical stage induce similar
changes in lipid metabolism. Br J Cancer. 119:847–854. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Park YH, Jung HH, Ahn JS and Im YH: Statin
induces inhibition of triple negative breast cancer (TNBC) cells
via PI3K pathway. Biochem Biophys Res Commun. 439:275–279. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sassano A and Platanias LC: Statins in
tumor suppression. Cancer Lett. 260:11–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jiang P, Mukthavaram R, Chao Y, Nomura N,
Bharati IS, Fogal V, Pastorino S, Teng D, Cong X, Pingle SC, et al:
In vitro and in vivo anticancer effects of mevalonate pathway
modulation on human cancer cells. Br J Cancer. 111:1562–1571. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Campbell MJ, Esserman LJ, Zhou Y,
Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx
C, et al: Breast cancer growth prevention by statins. Cancer Res.
66:8707–8714. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Risch HA: Hormonal etiology of epithelial
ovarian cancer, with a hypothesis concerning the role of androgens
and progesterone. J Natl Cancer Inst. 90:1774–1786. 1998.
View Article : Google Scholar : PubMed/NCBI
|
